title: The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis.
abstract: BACKGROUND
  Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts eosinophil maturation and promotes programmed cell death.
  
  
  OBJECTIVE
  We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug in patients with inadequately controlled, eosinophilic asthma.
  
  
  METHODS
  The search included the following databases: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register.
  
  
  METHODS
  A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of reslizumab for the treatment of inadequately controlled, eosinophilic asthma.
  
  
  METHODS
  Two reviewers independently extracted and verified pre-defined data fields.
  
  
  RESULTS
  Four publications including 5 RCTs that compared reslizumab with placebo. For the comparison of reslizumab with placebo, asthma exacerbation (odds ratio (OR) = 0.46, 95% confidence interval (CI) = 0.35 to 0.59, p <0.00001); a forced expiratory volume in 1 s (FEV1) (the standardized mean difference (SMD) = 0.16, 95%CI = 0.10 to 0.23, p <0.00001); Asthma Control Questionnaire (ACQ) score (the SMD = -0.26, 95%CI= -0.36 to -0.16, p <0.00001); blood eosinophil counts (the SMD = -475.62, 95%CI = -528.41 to -422.83, p <0.00001). Safety assessments included the proportion of individuals who withdrawn due to adverse event (AE) (OR = 0.60 95%CI = 0.38 to 1.17, p = 0.16) indicated that reslizumab was well tolerated.
  
  
  CONCLUSIONS
  The article didn't research the safety, efficacy of reslizumab with longer term.
  
  
  CONCLUSIONS
  This meta-analysis indicates that reslizumab to be an effective and safe treatment for inadequately controlled, eosinophilic asthma.
authors.affiliation: a Department of Respiratory Medicine , The Affiliated Hospital of Qingdao University , Qingdao , China.
authors.forename: Jinfeng
authors.initials: J
authors.lastname: Li
authors.affiliation: a Department of Respiratory Medicine , The Affiliated Hospital of Qingdao University , Qingdao , China.
authors.forename: Fangfang
authors.initials: F
authors.lastname: Wang
authors.affiliation: a Department of Respiratory Medicine , The Affiliated Hospital of Qingdao University , Qingdao , China.
authors.forename: Cunzhi
authors.initials: C
authors.lastname: Lin
authors.affiliation: a Department of Respiratory Medicine , The Affiliated Hospital of Qingdao University , Qingdao , China.
authors.forename: Jianxin
authors.initials: J
authors.lastname: Du
authors.affiliation: a Department of Respiratory Medicine , The Affiliated Hospital of Qingdao University , Qingdao , China.
authors.forename: Baohong
authors.initials: B
authors.lastname: Xiao
authors.affiliation: a Department of Respiratory Medicine , The Affiliated Hospital of Qingdao University , Qingdao , China.
authors.forename: Chunhua
authors.initials: C
authors.lastname: Du
authors.affiliation: a Department of Respiratory Medicine , The Affiliated Hospital of Qingdao University , Qingdao , China.
authors.forename: Jiaxing
authors.initials: J
authors.lastname: Sun
mesh_terms: D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000453:epidemiology*; D004311:Double-Blind Method; D004802:Eosinophilia / Q000453:epidemiology*; D006801:Humans; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012129:Respiratory Function Tests
chemical_list: D018927:Anti-Asthmatic Agents; D061067:Antibodies, Monoclonal, Humanized; C515492:reslizumab
keywords: Reslizumab; asthma; eosinophilic; meta-analysis; randomized controlled trial